Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase plus unfractionated heparin before primary PCI versus conventional primary PCI in acute myocardial infarction
2004-002241-12Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2005
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase and heparin in myocardial infarction (MI) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of death, cardiogenic shock, or congestive heart failure at 90 days. Started May 2005; status: completed.
02
Drugs
tenecteplaseheparin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2004-002241-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002241-12.